Drug Trial Radar · NCT04458051
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
767
Actual
Start
Aug 13, 2020
Primary completion
Nov 14, 2025
Study completion Nov 14, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
Conditions
- Primary Progressive Multiple Sclerosis
Interventions
TolebrutinibDrug
Pharmaceutical form: Film-coated Tablet Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- 6-month composite Confirmed Disability Progression (cCDP)Time frame: Up to approximately 60 months
Locations
277 sites in 42 countries. Site status is shown where the registry gives one.
UC San Diego ACTRI Site Number : 8400101
La Jolla, California
Collaborative Neuroscience Research Site Number : 8400045
Los Alamitos, California
Multiple Sclerosis Center- Site Number : 8400143
Los Angeles, California
Multiple Sclerosis Center of California Site Number : 8400135
Newport Beach, California
SC3 Research - Pasadena Site Number : 8400070
Pasadena, California
University of San Francisco, Sandler Neurosciences Center- Site Number : 8400137
San Francisco, California
Harbor UCLA Site Number : 8400088
Torrance, California
Regina Berkovich, MD, PhD Site Number : 8400059
West Hollywood, California
Advanced Neurosciences Research Site Number : 8400025
Fort Collins, Colorado
South Florida Neurology Associates Site Number : 8400029
Boca Raton, Florida
MS & Neuromuscular Center of Excellence Site Number : 8400172
Clearwater, Florida
University of Florida, Fixel Center for Neurology Site Number : 8400159
Gainesville, Florida
Neurology Associates, PA- Site Number : 8400004
Maitland, Florida
University of South Florida Site Number : 8400006
Tampa, Florida
Velocity Clinical Research Site Number : 8400003
Savannah, Georgia
Hawaii Pacific Neuroscience Site Number : 8400103
Honolulu, Hawaii
Consultants In Neurology- Site Number : 8400011
Northbrook, Illinois
Methodist Hospital Site Number : 8400164
Merrillville, Indiana
College Park Family Care Center Site Number : 8400044
Overland Park, Kansas
University of Kentucky Site Number : 8400106
Lexington, Kentucky
Ochsner Baptist Clinical Trials Unit (CTU)- Site Number : 8400107
New Orleans, Louisiana
International Neurorehabilitation Institute Site Number : 8400034
Lutherville, Maryland
Tufts Medical Center Site Number : 8400072
Boston, Massachusetts
University of Massachusetts Site Number : 8400014
Worcester, Massachusetts
Michigan Institute For Neurological Disorders Site Number : 8400058
Farmington Hills, Michigan
The Memorial Hospital- Site Number : 8400033
Owosso, Michigan
Mayo Clinic Site Number : 8400111
Rochester, Minnesota
Sharlin Health & Neurology Site Number : 8400093
Ozark, Missouri
University Of Nebraska- Site Number : 8400129
Omaha, Nebraska
Hackensack University Hospital Site Number : 8400047
Hackensack, New Jersey
University of New Mexico Site Number : 8400032
Albuquerque, New Mexico
Icahn School of Medicine at Mount Sinai (Department of Endoc Site Number : 8400038
New York, New York
Neurology Associates of Stony Brook Site Number : 8400042
Stony Brook, New York
Duke Neurological Disorders Clinic- Site Number : 8400098
Durham, North Carolina
Meridian Clinical Research, LLC- Site Number : 8400005
Raleigh, North Carolina
Atrium Health Wake Forest Baptist Site Number : 8400116
Winston-Salem, North Carolina
Riverhills Neuroscience - Norwood Site Number : 8400167
Cincinnati, Ohio
Cleveland Clinic Site Number : 8400125
Cleveland, Ohio
The Ohio State University Wexner Medical Center- Site Number : 8400150
Columbus, Ohio
The Boster Center for Multiple Sclerosis Site Number : 8400147
Columbus, Ohio
Showing 40 of 277 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.